{"disease":{"id":"egfr-alk-negative-advanced-nsclc","name":"egfr alk negative advanced nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06260553","title":"Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}